business, the start We you us. off and Thanks, deliver the We're Deb. continues execute our ambitious team and clear and to on entered a a joining to to great expectations. for with in focus our strategic afternoon, Insulet momentum thank Good XXXX. year and
strategic another expect of We and XXXX strong year growth progress. to be
for strong force our and for of revenue increased and it of delivered record QX. the growth to of any in today, customer for exceeded U.S. expectations, our is Omnipod XX% rest another represented driving achieved customer results and our management. quarter of revenue first the growth be outlook year. XX% offering and again we record for continues our Our global and a U.S. almost another starts. quarter once total We for U.S. QX, Omnipod new new transforming U.S. This revolutionary starts diabetes XX% X first
market. product are eliminating week, option and clearance leveraging basal named non-injection and By while basal-only type the received this X about pathway, we us diabetes patients with we receive innovation bringing with gives to provides diabetes GO. early into entry for comfortable Omnipod's FDA levels our for personal patients It Pod easing experience. the a is an insulin, comfortable management Omnipod in preset of and offering also a provides unique and Last insulin This XXXX. deliver technology. insulin people into tubeless physicians manager improved to treatment excited market We're
competitive high helping share to number pump take thanks with its market among tube and real-world market is of as as Omnipod and injection prescriptions, us large leader new impressive as continues well rapidly elegance strengthened the consistently leadership customer position the has diabetes to offerings. revenue It and disrupt of multiple to which ease Now our the new by our X, use starts outcomes. of from daily switches
across all and outcomes, to positioned life team's to simplified quality continue execution, XX/XX was capture. QX, of to us an to coupled with customers continue access, has estimated we In switches strong ease-of-use, from split legacy competitive XX/XX win X's our strong of a as coming of of and new tubed Omnipod the the mix our pumps historical mix compared clinical result market Omnipod MDI number segments.
Omnipod our unique of do. himself. and with everything one hoped you many has it's feedback patients the called a than and heard waited to X Omnipod and We we X this of what now product, type from years a hear He I've across for." patients I had solutions. from systems, whom recently X compared Omnipod X, customers almost its unmatched X,XXX type Omnipod speaks is operates and X, practitioner AID he benefits. clinic said, using who hundreds "Thank and on changer" both it of is for other a XX for truly to health He more "game you care use
echoed us our groups, age MDI by mission the Omnipod and learning X improve people of X. delivering on who is been age for decades to considered have over with X lives tell is patients diabetes. sentiment never would HCPs so XX that before including pumps about on people all their have and who Omnipod Omnipod experiencing many This span the of
to we system. our testament how Much of a this designed success is
improve we our boluses. that an every there the life is do to Plus innovations, need of customer better XXX% five with focus with target a algorithm to micro mind, minutes adjust drive to that basal or systems versus doses could disconnect. of we As rates offer each give We we no Omnipod Omnipod adjust all need other and simplify provides correction designed with day, quality how in X clear with the on outcomes. X,
adapts personalizes learns, for Our each user. algorithm and
set on Our with excellent we on incidence The XX,XXX at clinical life that Trade quality a hypoglycemia users and evidence of Omnipod and unmatched market. ADA month, with outcomes the by can X only competitors. are provide. Omnipod X And real-world lowest from larger more forward ATTD is of time at the building sharing achieve we able than Show next users the shared data look to data the range to
and users. These be to our with ease clinical for X's factor of are outcomes, use, form combined life-changing Omnipod proving
these on and objectives. Our against to market and excellence depends continues Omnipod, awareness with building leadership also team to of access our execute
can X diabetes global and these to who from need Our XX% underserved. countries remain the given serve approximately X people In XX% growing critically driving there advanced estimate drive and are solutions. markets are, important, vastly and pump insulin-intensive markets awareness X Approximately benefit and efforts today, for million we X, underpenetrated type access type with Omnipod. type are how we type have XX the
U.S. especially the market open X, type opportunity. solutions, a also in and U.S. we is unmet only massive is X, penetration is that insulin massive and will penetration means for further. much market a still digits Pump therapy type which need Omnipod have platform, and even The X single There in approximately low Omnipod below market the XX% international only market
was natural cap was adoption pump there all upon to estimates on tubed been have curve XX%, based but of adoption around pumps. consensus Prior a the Omnipod of these X, built
a by will and we game. X's otherwise to insulin game customers or our changes X simplicity, You've algorithm been heard an would outstanding for us bring Omnipod considered believe clinical never ease of advanced the use, outcomes call importantly, considered this never and, changer, it allow access driven have cost Omnipod pump. into and who us market
We are seeing already. this in our market feedback
is turn, are CGM by people to we raising to in for Omnipod and, awareness Additionally, way more CGM. bringing helping the pave
in quickly for X insulin becoming confident well is in indicate to XX% penetration CGM of alone. making new type care even type The over to Omnipod XX%, the standard potential penetration market X nearing delivery. more sources the platform Our market is us U.S. grow X's Omnipod
prescriptions through pharmacy strategy order local pick matter DME more mail in vast and our up is filled channel. U.S. to to makes and critical are much with the to Omnipod our growing through A of element And to presence periods. co-pays access pharmacy and or compared Omnipod ability convenient This Omnipod at X the of the access efficient, the X days product weeks channel. DASH no a lock-in affordable, in with the majority low
on with U.S. continue X make cost daily on no to access it through Omnipod with $XX the we with we number month X of X, difference experience customers start customer upfront to at market, affordable than it the channel, it. costs our would of to the large a vast any to putting pharmacy the multiple patient Omnipod less can Combined injections. parity invite pay of want for quickly people In relatively Omnipod for knew par Omnipod. Omnipod so majority U.S. price for we drive The DASH we
U.S. just is DASH covered X, Omnipod widely like the in Omnipod
Our the we seen. DASH X provide And in to Omnipod coverage focus operational of short approach we commitment quarterly updates have no a affordable Omnipod and fully incredibly drive team’s excellence terms, of In Omnipod and positioning Omnipod to both for similar with practical customer-centric took strong covered. enabled us are we broad-based time, us enormous DASH. period such, as now to level adoption X the for coverage will longer
Our study. including our clinical initiatives pivotal progress, type X to continue
type a study in last including will month to ever shortly three making recruiting XX diabetes X up we sites populations. across call on progress. great targeted people focus As XXX earnings underserved the a this after with U.S. and have our enrollment reminder, We and began with diverse be we’re conducted, largest the
can with Omnipod We’re X show do what people diabetes. X to for excited type
the pricing. Omnipod Both is our pivotal our progress and when is the last France be We participant RCT and for to building nearing We the in nearing X U.S. trial. will by several this additions are X randomized last premium fall. to the body expect been beneficial will and with Omnipod completion the X enrollment that evidence also the already over believe and participant strong making of clinical we study month RCT valuable controlled The in be complete great negotiating access study our study three type completion have years. we study last
Fueled what’s our by X, coming the are success working next. of already Omnipod on teams
type received TAM. We total our mentioned, for X in on in people Omnipod the is leadership at least Omnipod U.S., I build our the position. doubling U.S. further the U.S. alone, GO which we X GO As market million clearance addressable should estimate for
XXXX. We small in remain on expect commercial track select this to and begin a for in year locations pilot launch program a
us type competitive an market. and have individuals including indication portfolio due an for X with type success new We Omnipod space access. X several unique new of QX, like starts X pharmacy than tremendous strong. the which basis, our X lower On in factor as customer customer only an that absolute to X, has the our in form systems space, of X levels those represented U.S. across remains XX% such our historical channel starts percentage the In U.S. to estimated market, exist the AID all type Omnipod advantages type XX% the our in products. This is for of type
exciting is GX development Omnipod Libre Abbott quite congratulate an to Abbott’s on I to systems, That integration Our well CGM with want X and system we customers. efforts have the thrilled as for very CGM and be X of the value progress recent a only efforts partners Both continues their we’re our our to Libre moment We benefit iCGM of advancing our work on iOS customers offer and choice strengthen our accomplishment. best well. made will and to DexCom’s AID take as believe integrate progress as clearance future development to for both X with as milestones. Libre market of the current well and adding proposition. our that future current
we Germany customers bringing in marks the our Omnipod international in Omnipod year the in real-time excited Moving where the near device in this the and X benefits and international of HCPs. UK currently in HCPs and on both a fall, time first middle operations management our we delivering training the to are data introduce to markets, connected to we’re of markets. cloud to are This
in Our with our our rollout international of markets Omnipod of a broader these next launch countries beginning across year. the rollout marks X international stage
our to global capabilities, one manufacturing is to and mission. our plan ability Another critical our long-term are competitive of which growth our moats fulfill
supply navigate While levels, we pods components demand to base. our ahead producing headwinds, macro-related are global expanding of we customer for some continue and forecasted securing challenging ensuring
we Additionally, our our further building great facility will making Malaysia, new in global are strengthen progress capabilities. which manufacturing
of facility of on We placing begin are XXXX. the on manufacturing to this end us target the with take possession to and by our track year, expect build schedule in
sustainability across governance XXXX a our initiatives. published exciting number we of report week noting and environmental, social progress this Earlier
result and we one initiatives, of America’s we most all As to past were team the and work of Newsweek a quarter, growing the the fantastic of were executing success achievement entire pleased XXX. Insulet and company named we This to be responsible is global our dedication as added are mission. companies speaks by for also as our a This S&P to hard of as well having our XXXX. the for
structure the our Before we announced organizational I to over to I to this turn afternoon. the Wayde, want comment call on changes
we novel clinical And convenient gives us world-class and of getting transforming constantly are is is that. just data and started. momentum the it most as and cloud confident experience. aspects to is with can management X experience offering, Omnipod business X X results Our all delivering incredible to demonstrate. are Omnipod enjoying clearly we also a outcomes revolutionary Omnipod build we on therapy opportunity because is connectivity the customer our use the end-to-end improve diabetes
in to early and our some that, leaders with the have type and huge In make patients in we order we to reach In of space the internationally. millions expand capture efforts opportunities now our opportunity decided addition are that we to expand the there portfolio the therapy help, to a course, changes of need options. of And we market are to operate. those to X how we’ve
for invest customer growth in customers closer importantly, organization I I of time, we’ve execute. to look technology both our structure be integrate we working and our and at to a cloud has even of taken data and close local processes organizational and drive see things, capture year our team could and capabilities, a and elevate experience. stack well and It that almost growth, and most orient how our regional not continues we do our and markets entire role the palette analytics assumed to end-to-end the get the our continue opportunities proud CEO to order three full especially around more the in Over been to and expansion need and since momentum
we we today, two announced have as earlier July the effective new X. organization in created roles Therefore,
role. and Eric Strategy across on Benjamin, vision and product experience President and Customer management, The Officer take Executive first including Product of execution, the will driving our and Experience new for Chief end-to-end is responsible product Innovation franchise Vice this management customer enterprise. the
Engineering like for and to cybersecurity, for and and Insulet Vice each of The entire second into data President hardware and is the Mark leadership. responsible digital technology, behalf Chief Officer software On them architecture. Software information I’d Technology Group thank of Eric step engineering, this their role. new our of Mark congratulate system services and Field, team, will
in to we with more for in that U.S. for Global leaders, drive We a and our are international markets, structure growth Officer one transitioning to also announced two one had that another Chief international. effectively order commercial role a Commercial from distinct
provide time the Bret. We milestones to Bret everything Insulet our us, decision, pursue leaving Omnipod has result a has with the best of call he’s to He course during As period. Thank the services during that Insulet. important thank is role you, want of consulting he Bret Christensen other he opportunities. on of May moving transition the us here to He played his know to agreed well. and at launch an X many in so We I key channel for the pharmacy the Bret accomplished including wishes on X. as wish for all best and us all as today
the help structure efficiency, also innovations confident markets. work world we to in to people forward potential company’s time with to our terrific with the refinements Insulet entire to but new are diabetes. speed I the look organization growth of improve our continue living to not simplify the continue to around realize that us momentum, of accelerate continuing our and our international our will millions to lives mission only and to our making our with drive our team immense I’m market
that successful championing their Omnipod will thousands Omnipod market are X, with first people the be year the it people the to and way diabetes. adopting is a X for bring changing start to HCPs from what manage confident of we the to who and closing, helping marked strong diabetes are Insulet. In quarter another transforming benefit it.
lead well our sustainable are and creation expand to while consistently value innovation. employees to access and of we growth of industry a It continue Omnipod business are delivering, positioned to years growth for in company-wide to drive We globally come. generate to and effort the X investing to the takes all our
I over call Wayde. will to now turn the
